Align Technology (NASDAQ:ALGN – Get Free Report) and Nexalin Technology (NASDAQ:NXL – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.
Risk and Volatility
Align Technology has a beta of 1.74, indicating that its share price is 74% more volatile than the S&P 500. Comparatively, Nexalin Technology has a beta of 4.31, indicating that its share price is 331% more volatile than the S&P 500.
Valuation and Earnings
This table compares Align Technology and Nexalin Technology”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Align Technology | $4.03 billion | 2.95 | $410.35 million | $6.87 | 24.16 |
| Nexalin Technology | $300,000.00 | 3.58 | -$8.22 million | ($14.41) | -0.10 |
Align Technology has higher revenue and earnings than Nexalin Technology. Nexalin Technology is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
88.4% of Align Technology shares are owned by institutional investors. Comparatively, 0.7% of Nexalin Technology shares are owned by institutional investors. 0.7% of Align Technology shares are owned by company insiders. Comparatively, 16.9% of Nexalin Technology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Profitability
This table compares Align Technology and Nexalin Technology’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Align Technology | 11.83% | 15.96% | 10.48% |
| Nexalin Technology | -4,141.94% | -278.24% | -218.42% |
Analyst Ratings
This is a summary of current recommendations for Align Technology and Nexalin Technology, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Align Technology | 1 | 7 | 8 | 1 | 2.53 |
| Nexalin Technology | 1 | 1 | 0 | 0 | 1.50 |
Align Technology currently has a consensus target price of $193.08, suggesting a potential upside of 16.31%. Given Align Technology’s stronger consensus rating and higher possible upside, research analysts plainly believe Align Technology is more favorable than Nexalin Technology.
Summary
Align Technology beats Nexalin Technology on 12 of the 15 factors compared between the two stocks.
About Align Technology
Align Technology, Inc. designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth. The segment also provides Invisalign moderate, lite and express packages, and Invisalign go and Invisalign Go Plus; retention products, Invisalign training, and adjusting tools used by dental professionals during the course of treatment; and Invisalign Palatal Expander, a 3D printed orthodontic device; and 3D printing solutions. Its Imaging Systems and CAD/CAM Services segment offers iTero intraoral scanning system, a single hardware platform for restorative or orthodontic procedures; restorative software for general practitioner dentists, prosthodontists, periodontists, and oral surgeons; and orthodontists software for digital records storage, orthodontic diagnosis, and fabrication of printed models and retainers. This segment also provides Invisalign outcome simulator, a chair-side and cloud-based application for the iTero scanner; Invisalign progress assessment tool; Align Oral Health Suite, a digital interface designed to enhance dental consultations; and TimeLapse technology, which allows doctors or practitioners to compare a patient's historic 3D scans to the present-day scan, as well as subscription software, disposables, rentals, leases, pay per scan, and CAD/CAM software solutions. The company was incorporated in 1997 and is headquartered in Tempe, Arizona.
About Nexalin Technology
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.
Receive News & Ratings for Align Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Align Technology and related companies with MarketBeat.com's FREE daily email newsletter.
